Back to today’s briefing

Story perspectives

Rivaroxaban's Bleeding Risk Higher Than Aspirin, Study Reveals

2/15/2025

50 10

Summary

Story summary

A comprehensive analysis of nine trials with over 26,000 patients reveals that rivaroxaban poses a greater bleeding risk than aspirin, while dabigatran and apixaban maintain similar safety profiles. Despite low major bleeding rates across all treatments, doctors may lean towards apixaban or dabigatran, emphasizing the need to consider individual patient circumstances.

1 of 1

Story summary

A comprehensive analysis of nine trials with over 26,000 patients reveals that rivaroxaban poses a greater bleeding risk than aspirin, while dabigatran and apixaban maintain similar safety profiles. Despite low major bleeding rates across all treatments, doctors may lean towards apixaban or dabigatran, emphasizing the need to consider individual patient circumstances.